Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

類似資料

• Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
  著者:: Gengwei Huo, 等
  出版事項: (2023-02-01)
• First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
  著者:: Wenjie Liu, 等
  出版事項: (2023-07-01)
• Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
  著者:: Wenjie Liu, 等
  出版事項: (2024-02-01)
• Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
  著者:: Maojin You, 等
  出版事項: (2023-09-01)
• An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
  著者:: Michele Bartoletti, 等
  出版事項: (2022-07-01)